English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/217969
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

AuthorsBoettler, Tobias; Marjot, Thomas; Newsome, Philip N.; Mondelli, Mario U.; Maticic, Mojca; Cordero, Elisa; Jalan, Rajiv; Moreau, Richard; Cornberg, Markus; Berg, Thomas
KeywordsACE-I
Angiotensin-converting enzyme inhibitor
ACE2
Angiotensin-converting enzyme 2
ACLF
Acute-on-chronic liver failure
ALT
Alanine aminotransferase
AST
Aspartate aminotransferase
COVID-19
Coronavirus disease 2019
EGD
Esophagogastroduodenoscopy
ERC
Endoscopic retrograde cholangiography
HCC
Hepatocellular carcinoma
MELD
Model for end-stage liver disease
MAFLD
Metabolic-dysfunction associated fatty liver disease
NASH
Non-alcoholic steatohepatitis
NUC
Nucleoside analogue
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
ULN
Upper limit of normal
Issue Date4-Aug-2020
PublisherElsevier BV
CitationJHEP Reports (2020)
AbstractDuring the early stages of the COVID-19 pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. In the meantime, many countries and healthcare systems have been, or are still overwhelmed by the pandemic, significantly impacting on the care of this group of patients, whilst others have started to return towards their usual routine. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the course of the disease have to be kept in mind when caring for patients with COVID-19. Thus, this review should serve as an update on the previous position paper summarizing the evidence for liver disease involvement during COVID-19 and also provid
Publisher version (URL)https://doi.org/10.1016/j.jhepr.2020.100169
URIhttp://hdl.handle.net/10261/217969
DOIhttp://dx.doi.org/10.1016/j.jhepr.2020.100169
ISSN2589-5559
Appears in Collections:(IBIS) Artículos
(VICYT) Colección Especial COVID-19
Files in This Item:
File Description SizeFormat 
Impact of COVID-19 on the care of patients.pdf1,59 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.